Sign in Subscribe

targeted-therapy

A collection of 104 issues

PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

Skip to content The CRC Digest ◇ RESEARCH PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep) This

Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer

Skip to content The CRC Digest Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer A retrospective study of 150 patients with KRAS-mutant colon cancer investigated whether serial thoracic CT demonstrates progressive enlargement of the main pulmonary artery during bevacizumab-based chemotherapy. (Cancer Chemother Pharmacol) This content is informational

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial

Skip to content The CRC Digest Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)

Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors

Skip to content The CRC Digest ▸ TREATMENT Phase 1 trial evaluates oral KRAS G12D inhibitor GFH375 in advanced solid tumors A phase 1 dose-escalation trial evaluated GFH375, an oral compound that targets both active and inactive states of KRAS G12D proteins, in patients with advanced solid tumors harboring the KRAS

AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides

Skip to content The CRC Digest ◇ RESEARCH AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides HistoNav, a deep-learning algorithm analyzing H&E-stained tissue samples from 2,095 patients, identified low-, intermediate-, and high-risk groups with 5-year disease-specific survival rates of 93.2%, 84.

Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic CRC A matching-adjusted indirect comparison evaluated sotorasib combined with panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only

Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

Skip to content The CRC Digest ♥ LIVING WITH CRC Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer

Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab

Skip to content The CRC Digest ▸ TREATMENT Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal

FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027

Skip to content The CRC Digest ● REGULATORY FDA delays decision on zanzalintinib plus Tecentriq for metastatic colorectal cancer until March 2027 The FDA has extended its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in combination with Roche's Tecentriq to March 2027 while awaiting updated safety and